Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients

• Published in: BMC cancer 2017-11, Vol.17 (1), p.786-786, Article 786
• Main Authors: Takeshita, Takashi, Yamamoto, Yutaka, Yamamoto-Ibusuki, Mutsuko, Sueta, Aiko, Tomiguchi, Mai, Murakami, Keiichi, Omoto, Yoko, Iwase, Hirotaka
• Format: Article
• Language: English
• Subjects: Acquired endocrine therapy resistance; Analysis; Breast cancer; Cancer patients; Cancer treatment; Care and treatment; Cell-free DNA; E380Q mutation; ESR1 mutations; Estradiol; Genetic aspects; Health aspects; Medical schools; Metastatic breast cancer
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-017-3779-2

ESR1 mutations have attracted attention as a potentially important marker and treatment target in endocrine therapy-resistant breast cancer patients. The E380Q mutation, which is one of the ESR1 mutations, is associated with estradiol (E2) hypersensitivity, increased DNA binding to the estrogen response element, and E2-independent constitutive trans-activation activity, but its frequency in ESR1 mutations remains unknown. The present study aimed to investigate the E380Q mutation in comparison with the other representative ESR1 mutations. We screened a total of 62 patients (66 tumor tissues and 69 plasma cell-free DNA (cfDNA)) to detect ESR1 mutations (E380Q, Y537S, Y537N, Y537C, and D538G) using droplet-digital polymerase chain reaction. Plasma was collected at more than two points of the clinical course, in whom changes of ESR1 mutations under treatment were investigated. We detected ESR1 mutations in 21% (12/57) of MBCs. The E380Q ESR1 mutation was found in 16% (2/12) and the other ESR1 LBD mutations were five (41.6%) of Y537S, and four each (33.3%) of D538G, Y537N, and Y537C, in 12 ESR1 mutant breast cancer patients. Five tumors had multiple ESR1 mutations: three had double ESR1 mutations; Y537S/E380Q, Y37S/Y537C, and Y537S/D538G, and two had triple ESR1 mutations; Y537S/Y537N/D538G. In plasma cfDNA analysis, the E380Q mutation was not detected, but increases in other ESR1 mutations were detected in 46.2% (6/13) of MBC patients under treatment. We have shown that there are distinct populations of ESR1 mutations in metastatic tissue and plasma. Each ESR1 mutation may have different clinical significance, and it will be necessary to investigate them all.